MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis
EF Morand, M Leech, J Bernhagen - Nature reviews Drug discovery, 2006 - nature.com
Macrophage migration inhibitory factor (MIF) is well established as a key cytokine in immuno-
inflammatory diseases such as rheumatoid arthritis. Inflammation is now also recognized as …
inflammatory diseases such as rheumatoid arthritis. Inflammation is now also recognized as …
The BAFF/APRIL system in SLE pathogenesis
Systemic lupus erythematosus (SLE) is characterized by multisystem immune-mediated
injury in the setting of autoimmunity to nuclear antigens. The clinical heterogeneity of SLE …
injury in the setting of autoimmunity to nuclear antigens. The clinical heterogeneity of SLE …
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
The introduction of biologics, especially tumour necrosis factor (TNF) inhibitors, has
revolutionized the management of chronic inflammatory diseases. However, at least one …
revolutionized the management of chronic inflammatory diseases. However, at least one …
[HTML][HTML] Trial of anifrolumab in active systemic lupus erythematosus
Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
Definition and initial validation of a lupus low disease activity state (LLDAS)
Aims Treating to low disease activity is routine in rheumatoid arthritis, but no comparable
goal has been defined for systemic lupus erythematosus (SLE). We sought to define and …
goal has been defined for systemic lupus erythematosus (SLE). We sought to define and …
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease
characterized by altered balance of activity between effector and regulatory CD4+ T cells …
characterized by altered balance of activity between effector and regulatory CD4+ T cells …
Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids
Objective Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine whose
involvement in tumor necrosis factor α (TNFα) synthesis and T cell activation suggests a role …
involvement in tumor necrosis factor α (TNFα) synthesis and T cell activation suggests a role …
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
Background Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …
Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2
JL Gregory, EF Morand, SJ McKeown… - The Journal of …, 2006 - journals.aai.org
Macrophage migration inhibitory factor (MIF) was originally identified for its ability to inhibit
the random migration of macrophages in vitro. MIF is now recognized as an important …
the random migration of macrophages in vitro. MIF is now recognized as an important …